P & G Hygiene (PGHH)

FairStock Score: 45/100 — MIXED

Score breakdown: P/E: 0/3 · ROCE: 2/2 · Growth: 1/2 · Dividend: 0/1

Key Financials

Strengths

• Zero-debt balance sheet with ₹559 Cr free cash flow provides complete financial flexibility
• Exceptional capital efficiency: ROE 116.62% and ROCE 103.79%
• High promoter holding of 70.64% aligns management with minority investors
• Piotroski F-Score 8/9 and Altman Z-Score 17.67 indicate strong financial health
• Durable personal-care brand moat supports premium pricing and a 1.50% dividend yield

Concerns

• Near-flat sales growth of 0.56% raises questions about volume growth and category maturity
• Extremely expensive valuation: P/E 42.87, P/B 45.93, PEG 7.63; price far above Graham Number ₹1,162 and DCF ₹3,755
• Negative margin of safety at -876.59% leaves no room for error
• Negative EV/EBITDA of -9.16 suggests earnings quality or enterprise-value distortions need scrutiny

AI Analysis

Let me start with what I admire. P&G Hygiene is exactly the kind of franchise I would like to own at the right price. It has zero debt, generates ₹559 crore of free cash flow, and earns 116.62% on equity and 103.79% on capital. Promoters own 70.64%, so my interests are aligned with people who know the business. The Altman Z-score of 17.67 and Piotroski score of 8 out of 9 tell me this is financially sound and well-run. In personal care, the P&G brand portfolio gives it a durable moat. But Graham taught me to separate quality from price. At ₹10,427, the market capitalisation is ₹36,846 crore. That's 42.87 times earnings and 45.93 times book value. For that price, I need growth. What do I see? Sales grew only 0.56%. Yes, profits rose 20.05%, and the latest quarter shows ₹301 crore net profit on ₹1,262 crore sales, which is impressive. But a company growing its top line less than one percent is not a fast grower. The profit growth may simply be margin expansion, cost savings, or a low base. The mathematics are clear. The Graham Number is ₹1,162.31; the DCF value is ₹3,755.50. At ₹10,427, I am being asked to pay almost nine times a conservative intrinsic estimate. Margin of safety is -876%. Even the PEG ratio of 7.63 tells me the market has priced in decades of perfection. The dividend yield of 1.50% does not compensate me for waiting. This is a wonderful business. It is not a wonderful investment for me today. I would wait for a lower price or for evidence that sales growth is genuinely accelerating. With zero debt and high cash generation, the risk in owning it over the long term is lower than for an average company, but paying 43 times earnings for a flat top line is not value investing. It is hope.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer